论文信息 - ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of theEuropeanSocietyofCardiology(ESC)anddevelopedincollaboration

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of theEuropeanSocietyofCardiology(ESC)anddevelopedincollaboration

Authors/Task Force Members: Lars Rydén* (ESC Chairperson) (Sweden), Peter J. Grant* (EASD Chairperson) (UK), Stefan D. Anker (Germany), Christian Berne (Sweden), Francesco Cosentino (Italy), Nicolas Danchin (France), Christi Deaton (UK), Javier Escaned (Spain), Hans-Peter Hammes (Germany), Heikki Huikuri (Finland), Michel Marre (France), Nikolaus Marx (Germany), Linda Mellbin (Sweden), Jan Ostergren (Sweden), Carlo Patrono (Italy), Petar Seferovic (Serbia), Miguel Sousa Uva (Portugal), Marja-Riita Taskinen (Finland), Michal Tendera (Poland), Jaakko Tuomilehto (Finland), Paul Valensi (France), Jose Luis Zamorano (Spain)

[1] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[2] B. Obermayer-Pietsch,et al. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. , 2013, Human reproduction.

[3] L. Rydén,et al. Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes , 2013, European journal of preventive cardiology.

[4] M. Huijberts,et al. Response to Comment on: Hanssen et al. Associations Between the Ankle-Brachial Index and Cardiovascular and All-Cause Mortality Are Similar in Individuals Without and With Type 2 Diabetes: Nineteen-Year Follow-Up of a Population-Based Cohort Study. Diabetes Care 2012;35:1731–1735 , 2013, Diabetes Care.

[5] J. Beckman,et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[6] M. Mack,et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7] W. Cushman,et al. Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial , 2013, Diabetes Care.

[8] Mikael Fogelholm,et al. Faculty of 1000 evaluation for Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013 .

[9] P. Erwin,et al. Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients. , 2013, The Annals of thoracic surgery.

[10] Lynn A. Sleeper,et al. Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: Results From the FREEDOM Trial , 2013, Circulation.

[11] J. Beckman,et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. , 2013, European heart journal.

[12] S. Inzucchi,et al. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[13] Akshay S. Desai,et al. Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.

[14] Nish Chaturvedi,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[15] M. Hanefeld,et al. Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? , 2012, European journal of heart failure.

[16] Markus Abt,et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[17] M. V. van Driel,et al. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus. , 2012, The Cochrane database of systematic reviews.

[18] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[20] J. Dillinger,et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. , 2012, American heart journal.

[21] H. Heidbuchel,et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II) , 2012, European journal of preventive cardiology.

[22] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[23] U. Nöthlings,et al. Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis. , 2012, Archives of internal medicine.

[24] Karel G M Moons,et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study , 2012, BMJ : British Medical Journal.

[25] T. Vassiliades,et al. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. , 2012, The Annals of thoracic surgery.

[26] P. Ridker,et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. , 2012, JAMA.

[27] R. Collins,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[28] Amir Lerman,et al. The Assessment of Endothelial Function: From Research Into Clinical Practice , 2012, Circulation.

[29] S. Shoelson,et al. Metabolic Syndrome, Insulin Resistance, and Roles of Inflammation – Mechanisms and Therapeutic Targets , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[30] Salim Yusuf,et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[31] K. Khunti,et al. Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[32] A. Akhmedov,et al. Gene Silencing of the Mitochondrial Adaptor p66Shc Suppresses Vascular Hyperglycemic Memory in Diabetes , 2012, Circulation research.

[33] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[34] F. Santilli,et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes , 2012, Journal of thrombosis and haemostasis : JTH.

[35] K. Swedberg,et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. , 2012, Journal of the American College of Cardiology.

[36] F. Rutten,et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes , 2012, Diabetologia.

[37] Carin M. Van Gelder,et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. , 2012, JAMA.

[38] P. Seferovic,et al. Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes. , 2012, International journal of cardiology.

[39] Sean M. O'Brien,et al. Comparative effectiveness of revascularization strategies. , 2012, The New England journal of medicine.

[40] G. Stone,et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[41] J. Frampton. Ranibizumab , 2012, Drugs.

[42] Ashish S Shah,et al. What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors. , 2012, The Annals of thoracic surgery.

[43] E. Omerovic,et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). , 2012, European heart journal.

[44] J. Shaw,et al. Current controversies in the use of haemoglobin A1c , 2012, Journal of internal medicine.

[45] Raimund Erbel,et al. [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.

[46] Jeroen J. Bax,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[47] M. Holmes-Rovner,et al. Interventions for providers to promote a patient-centred approach in clinical consultations. , 2002, The Cochrane database of systematic reviews.

[48] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[49] R. Shephard. Physical Activity Advice Only or Structured Exercise Training and Association With HbA1c Levels in Type 2 Diabetes: A Systematic Review and Meta-analysis , 2012 .

[50] V. Thourani,et al. Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome , 2012 .

[51] C. Rowley. Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[52] P. Toth. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[53] C. Gazzaruso,et al. Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients , 2012, Internal and Emergency Medicine.

[54] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[55] R. de Caterina,et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. , 2011, European heart journal.

[56] A. Davies,et al. Chapter V: Diabetic foot. , 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[57] M. Mack,et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. , 2011, The Annals of thoracic surgery.

[58] A. Vaag,et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials , 2011, BMJ : British Medical Journal.

[59] P. Nilsson,et al. Trends in blood pressure control in patients with type 2 diabetes – Data from the Swedish National Diabetes Register (NDR) , 2011, Blood pressure.

[60] C. Meisinger,et al. Iconographies supplémentaires de l'article : Gender-Specific Short and Long-Term Mortality in Diabetic Versus Nondiabetic Patients With Incident Acute Myocardial Infarction in the Reperfusion Era (the MONICA/KORA Myocardial Infarction Registry) , 2011 .

[61] H. Bøtker,et al. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). , 2011, The American journal of cardiology.

[62] Thomas W. Gardner,et al. The restore study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema , 2011 .

[63] J. Lindström,et al. Shifting from glucose diagnostic criteria to the new HbA1c criteria would have a profound impact on prevalence of diabetes among a high‐risk Spanish population , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[64] S. Wild,et al. Do men develop type 2 diabetes at lower body mass indices than women? , 2011, Diabetologia.

[65] M. Trovati,et al. Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up , 2011, Diabetes Care.

[66] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[67] MartinAdiels,et al. Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects , 2011 .

[68] N. Perico,et al. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. , 2011, International journal of cardiology.

[69] P. Valensi,et al. Cardiovascular Risk Prediction Is Improved by Adding Asymptomatic Coronary Status to Routine Risk Assessment in Type 2 Diabetic Patients , 2011, Diabetes Care.

[70] Makoto Watanabe,et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. , 2011, Archives of internal medicine.

[71] M. Malik,et al. Reflex and Tonic Autonomic Markers for Risk Stratification in Patients With Type 2 Diabetes Surviving Acute Myocardial Infarction , 2011, Diabetes Care.

[72] Kamlesh Khunti,et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial , 2011, The Lancet.

[73] Lawrence A Leiter,et al. Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials , 2011, Diabetes, obesity & metabolism.

[74] P. Kolh,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[75] E. Boersma,et al. Comparison of diagnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome , 2011, Heart.

[76] S. Bangalore,et al. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials , 2011, Circulation.

[77] P. Wilson,et al. Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia , 2011, Diabetes Care.

[78] M. Landray,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[79] M. Briel,et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. , 2011, European heart journal.

[80] Moshe Levi,et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[81] J. Borén,et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[82] S. Gudbjörnsdottir,et al. Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register , 2011, PloS one.

[83] S. Heller,et al. Hypoglycemia and Cardiovascular Risks , 2011, Diabetes Care.

[84] B. Balkau,et al. Influence of blood glucose on heart rate and cardiac autonomic function. The DESIR study , 2011, Diabetic Medicine.

[85] B. Zinman,et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. , 2011, Archives of internal medicine.

[86] Michael E. Miller,et al. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes , 2011 .

[87] K. Berra. Does Nurse Case Management Improve Implementation of Guidelines for Cardiovascular Disease Risk Reduction? , 2011, The Journal of cardiovascular nursing.

[88] Yves Cottin,et al. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. , 2011, Archives of cardiovascular diseases.

[89] N. Marchionni,et al. Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials , 2011, Diabetes, obesity & metabolism.

[90] Mark Woodward,et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes , 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[91] R. Santos-Oliveira,et al. Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts , 2011, Diabetologia.

[92] D. Angiolillo,et al. Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome , 2011, Circulation.

[93] P. Touboul,et al. Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis , 2011, Journal of cardiovascular pharmacology.

[94] C. Bhamidipati,et al. Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting. , 2011, The Journal of thoracic and cardiovascular surgery.

[95] P. Nilsson,et al. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register , 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[96] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[97] J. Eriksson,et al. HbA1c in diagnosing and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[98] W. Chan,et al. Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure , 2010, Circulation. Heart failure.

[99] P. Whincup,et al. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study , 2011, Diabetologia.

[100] DavidAguilar,et al. Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure , 2011 .

[101] Finn Gustafsson,et al. 2010 Focused Update of ESC Guidelines on Device Therapy in Heart Failure , 2011 .

[102] B. Gersh. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2011 .

[103] W. Elliott. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes , 2011 .

[104] M. Ruth,et al. Downregulation of Adipose Tissue Fatty Acid Trafficking in Obesity: A Driver for Ectopic Fat Deposition? , 2011 .

[105] M. Cheitlin. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2011 .

[106] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[107] Jeroen J. Bax,et al. Multimodality imaging in diabetic heart disease. , 2011, Current problems in cardiology.

[108] M. Soma,et al. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. , 2011, Current drug metabolism.

[109] Donald R. Lynch. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[110] M. Rutter,et al. What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies , 2011, Heart Failure Reviews.

[111] M. Taskinen,et al. [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[112] J. Zhang,et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study , 2011, Diabetologia.

[113] V. Gebski,et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study , 2011, Diabetologia.

[114] C. Meisinger,et al. Gender-Specific short and long-term mortality in diabetic versus nondiabetic patients with incident acute myocardial infarction in the reperfusion era (the MONICA/KORA Myocardial Infarction Registry). , 2010, The American journal of cardiology.

[115] G. Stone,et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). , 2010, Journal of the American College of Cardiology.

[116] B. Fernhall,et al. Exercise and type 2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement. Exercise and type 2 diabetes. , 2010, Medicine and science in sports and exercise.

[117] L. Rydén,et al. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart. , 2010, European heart journal.

[118] D. van der A,et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes , 2010, Diabetologia.

[119] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[120] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[121] J. Ferrières,et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. , 2010, The Journal of clinical endocrinology and metabolism.

[122] Simon P. Harding,et al. Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) , 2010, Diabetes Care.

[123] Ferdinando Giacco,et al. Oxidative stress and diabetic complications. , 2010, Circulation research.

[124] Beverley Balkau,et al. Glycemic Thresholds for Diabetes-Specific Retinopathy , 2010, Diabetes Care.

[125] Yun-Tao Zhao,et al. Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials , 2010, Heart.

[126] H. Huikuri,et al. Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. , 2010, Heart rhythm.

[127] B. Frier,et al. Impaired awareness of hypoglycaemia: a review. , 2010, Diabetes & metabolism.

[128] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[129] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[130] Rena R Wing,et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. , 2010, Archives of internal medicine.

[131] M. Keltai,et al. Coronary Heart Disease Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2010 .

[132] S. Stevens,et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial , 2010, European heart journal.

[133] Rodica Pop-Busui,et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.

[134] R. Klein,et al. Are Individuals With Diabetes Seeing Better? , 2010, Diabetes.

[135] Jennifer K. Sun,et al. Effect of systemic medications on onset and progression of diabetic retinopathy , 2010, Nature Reviews Endocrinology.

[136] Walter T Ambrosius,et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[137] A. Kengne,et al. The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock. , 2010, Progress in cardiovascular diseases.

[138] The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[139] A. Keech,et al. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes , 2010, Diabetologia.

[140] W. Laskey,et al. Evolution of Percutaneous Coronary Intervention in Patients with Diabetes , 2010, Diabetes Care.

[141] U. Nöthlings,et al. Lifestyle factors and mortality among adults with diabetes: findings from the European Prospective Investigation into Cancer and Nutrition–Potsdam study * , 2010, Journal of diabetes.

[142] P. Giral,et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. , 2010, Pharmacology & therapeutics.

[143] Sumit R. Majumdar,et al. Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database , 2010, Diabetes Care.

[144] D. Grobbee,et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[145] A. Thanopoulou,et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. , 2010, The New England journal of medicine.

[146] C. Dennison,et al. Randomized Trials of Nursing Interventions for Secondary Prevention in Patients With Coronary Artery Disease and Heart Failure: Systematic Review , 2010, The Journal of cardiovascular nursing.

[147] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[148] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[149] J. Tuomilehto,et al. Cardiovascular Disease Mortality in Europeans in Relation to Fasting and 2-h Plasma Glucose Levels Within a Normoglycemic Range , 2010, Diabetes Care.

[150] M. Laakso,et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[151] M. Laakso,et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[152] E. Salpeter,et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2010, The Cochrane database of systematic reviews.

[153] F. Santilli,et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus , 2010, Journal of thrombosis and haemostasis : JTH.

[154] Veronica K Jamnik,et al. The Role of Physical Activity in Type 2 Diabetes Prevention: Physiological and Practical Perspectives , 2010, The Physician and sportsmedicine.

[155] A. Stadlmayr,et al. A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[156] A. Rissanen,et al. Take Action to Prevent Diabetes – The IMAGE Toolkit for the Prevention of Type 2 Diabetes in Europe , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[157] C. Vlachopoulos,et al. Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness , 2011 .

[158] M. Grant,et al. The promise of cell-based therapies for diabetic complications: challenges and solutions. , 2010, Circulation research.

[159] P. Serruys,et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. , 2010, Journal of the American College of Cardiology.

[160] J. Fleg,et al. Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial , 2010, Diabetes Care.

[161] P. Damman,et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. , 2010, Journal of the American College of Cardiology.

[162] C. Cannon. Balancing the benefits of statins versus a new risk—diabetes , 2010, The Lancet.

[163] V. Fonseca. Effects of β-blockers on glucose and lipid metabolism , 2010, Current medical research and opinion.

[164] G. Angelini,et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. , 2010, Journal of the American College of Cardiology.

[165] S. Klein,et al. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications , 2010, Hepatology.

[166] B. Bozkurt,et al. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. , 2010, The American journal of cardiology.

[167] Michael E. Miller,et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study , 2010, BMJ : British Medical Journal.

[168] Costantina Manes,et al. Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy , 2010, Circulation.

[169] D. Nieman,et al. Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates , 2010 .

[170] G. Moneta,et al. Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[171] S. Werns. Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes , 2010 .

[172] J. Tardif,et al. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. , 2010, The American journal of cardiology.

[173] J. Pankow,et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study , 2010, Acta Diabetologica.

[174] M. Laakso,et al. Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance , 2010, Diabetologia.

[175] Regina M. Hardison,et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease: Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction , 2009, Circulation.

[176] V. Mohan,et al. Moving to an A1C-Based Diagnosis of Diabetes Has a Different Impact on Prevalence in Different Ethnic Groups , 2009, Diabetes Care.

[177] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[178] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[179] Lei Zhang,et al. Performance of an A1C and Fasting Capillary Blood Glucose Test for Screening Newly Diagnosed Diabetes and Pre-Diabetes Defined by an Oral Glucose Tolerance Test in Qingdao, China , 2009, Diabetes Care.

[180] Antonio Colombo,et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[181] R. Klein,et al. Rates of Progression in Diabetic Retinopathy During Different Time Periods , 2009, Diabetes Care.

[182] Harald Darius,et al. Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery Disease , 2009, Circulation.

[183] David M Nathan,et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[184] M. Robson,et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. , 2009, Journal of the American College of Cardiology.

[185] 入江潤一郎,et al. Glucose control and vascular complications in veterans with type 2 diabetes , 2009 .

[186] G. Reboldi,et al. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus , 2009, Expert review of cardiovascular therapy.

[187] S. Grundy,et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[188] Seung‐Jung Park,et al. Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study. , 2009, JACC. Cardiovascular interventions.

[189] Jeroen J. Bax,et al. The prognostic value of impaired walking distance on long-term outcome in patients with known or suspected peripheral arterial disease. , 2009, European Journal of Vascular and Endovascular Surgery.

[190] M. B. Jensen,et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[191] K. Reinier,et al. Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation , 2009, Diabetes Care.

[192] Deepak L. Bhatt,et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry , 2009, European heart journal.

[193] Thomas E. Moritz,et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes , 2009, Diabetologia.

[194] Mark Woodward,et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[195] A. Hughes,et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial , 2009, Diabetologia.

[196] N. J. Wareham,et al. Cardiovascular risk assessment scores for people with diabetes: a systematic review , 2009, Diabetologia.

[197] H. Parving,et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. , 2009, Annals of internal medicine.

[198] J. Shaw,et al. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[199] R. Blumenthal,et al. Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk A Scientific Statement From the American Heart Association , 2009, Circulation.

[200] Michael J. Pencina,et al. Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[201] Maria Mori Brooks,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[202] P. Fitzgerald,et al. Prospective, Multicenter, Randomized Trial to ssess Efficacy of Pioglitazone on In-Stent eointimal Suppression in Type 2 Diabetes OPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study) , 2022 .

[203] J. McMurray,et al. Pharmacologic management of patients with both heart failure and diabetes , 2009, Current heart failure reports.

[204] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[205] A. Hingorani,et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis , 2009, The Lancet.

[206] T. Valle,et al. Ten-Year Mortality and Cardiovascular Morbidity in the Finnish Diabetes Prevention Study—Secondary Analysis of the Randomized Trial , 2009, PloS one.

[207] Deepak L. Bhatt,et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). , 2009, The American journal of cardiology.

[208] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[209] W. Ahmad. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .

[210] G. Lip,et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. , 2009, European heart journal.

[211] F. Crea,et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. , 2009, European heart journal.

[212] E. Barrett,et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. , 2009, JAMA.

[213] H. Krumholz,et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. , 2009, JAMA.

[214] S. Pocock,et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials , 2009, The Lancet.

[215] K. Kotseva,et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[216] Philip M Clarke,et al. Development of life-expectancy tables for people with type 2 diabetes. , 2009, European heart journal.

[217] A. Smit,et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus , 2009, Diabetologia.

[218] G. Mancia,et al. Mechanisms of hypertension in the cardiometabolic syndrome , 2009, Journal of hypertension.

[219] Ronald Klein,et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. , 2009, Ophthalmology.

[220] P. Wilson,et al. Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial , 2009, Diabetes Care.

[221] D. Levy,et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study , 2009, The Lancet.

[222] M. Ihnat,et al. Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? , 2009, The Journal of clinical endocrinology and metabolism.

[223] Arturo Evangelista,et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[224] J. Lindström,et al. Tools for Predicting the Risk of Type 2 Diabetes in Daily Practice , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[225] A Gray,et al. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. , 2009, Health technology assessment.

[226] Giuseppe Mancia,et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.

[227] A. Keech,et al. Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.

[228] F. Ovalle. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .

[229] G. Moneta. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2009 .

[230] J. Tamsma,et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. , 2009, The New England journal of medicine.

[231] R. Stolk,et al. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. , 2009, The British journal of general practice : the journal of the Royal College of General Practitioners.

[232] J. Tuomilehto,et al. High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population , 2008, BMC public health.

[233] C. Cannon. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. , 2008, The American journal of cardiology.

[234] L. Rydén,et al. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial , 2008, Heart.

[235] L. Rydén,et al. Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes , 2008, European journal of heart failure.

[236] F. Sacks,et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients , 2008, Diabetes & vascular disease research.

[237] R. Collins,et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes , 2008, Journal of hypertension.

[238] R. Klein,et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials , 2008, The Lancet.

[239] H. Parving,et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial , 2008, The Lancet.

[240] P. Macfarlane,et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.

[241] E. Antman,et al. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.

[242] Rury R Holman,et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. , 2008, The New England journal of medicine.

[243] S. Grundy,et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[244] Björn Eliasson,et al. Risk Prediction of Cardiovascular Disease in Type 2 Diabetes , 2008, Diabetes Care.

[245] R. D'Agostino,et al. Effect of Aging on A1C Levels in Individuals Without Diabetes , 2008, Diabetes Care.

[246] M. Pfisterer,et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis , 2008, BMJ : British Medical Journal.

[247] J. Liao. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.

[248] O. Pedersen,et al. Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes , 2008, Diabetes Care.

[249] E. Tuzcu,et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. , 2008, Journal of the American College of Cardiology.

[250] G. Angelini,et al. Inadequate Blood Glucose Control Is Associated With In-Hospital Mortality and Morbidity in Diabetic and Nondiabetic Patients Undergoing Cardiac Surgery , 2008, Circulation.

[251] C. Lamendola,et al. Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects. , 2008, The American journal of cardiology.

[252] Martin Adiels,et al. Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[253] O. Faergeman,et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial , 2008, The Lancet.

[254] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[255] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[256] E. Hannan,et al. Drug-Eluting Stents vs Coronary-Artery Bypass Grafting in Multivessel Coronary Disease , 2008 .

[257] Karl Swedberg,et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[258] E. Topol,et al. Facilitated PCI in patients with ST-elevation myocardial infarction. , 2008, The New England journal of medicine.

[259] R. Kloner,et al. Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection. , 2008, Circulation.

[260] W. Saris,et al. Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[261] R. McKelvie,et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. , 2008, European heart journal.

[262] L. Opie. Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia , 2008, Circulation.

[263] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[264] L. Rydén,et al. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[265] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[266] G. De Backer,et al. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. , 2008, Atherosclerosis.

[267] W. Laskey,et al. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. , 2008, JACC. Cardiovascular interventions.

[268] T. Lüscher,et al. Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[269] Bendix Carstensen,et al. Measurement of blood glucose: comparison between different types of specimens , 2008, Annals of clinical biochemistry.

[270] W. Rathmann,et al. Prediction of Mortality Using Measures of Cardiac Autonomic Dysfunction in the Diabetic and Nondiabetic Population , 2008, Diabetes Care.

[271] H. Krumholz,et al. Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk , 2008, Circulation.

[272] O. Pedersen,et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[273] Gregory Y H Lip,et al. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.

[274] R Peto,et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[275] L. Rydén,et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. , 2007, European heart journal.

[276] William Wijns,et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[277] Haynes Rb,et al. Interventions for enhancing medication adherence (Review) , 2008 .

[278] R B Haynes,et al. Interventions for enhancing medication adherence. , 2008, The Cochrane database of systematic reviews.

[279] G. Gill,et al. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—the ‘dead in bed’ syndrome revisited , 2008, Diabetologia.

[280] G. Davı̀,et al. Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.

[281] J. Cornuz,et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. , 2007, JAMA.

[282] M. Hamer,et al. Intake of fruit, vegetables, and antioxidants and risk of type 2 diabetes: systematic review and meta-analysis , 2007, Journal of hypertension.

[283] P. Gurbel,et al. The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients , 2007, Diabetes.

[284] J. Armitage,et al. The safety of statins in clinical practice , 2007, The Lancet.

[285] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[286] J. Lasalle,et al. The team approach to diabetes management: partnering with patients , 2007, International journal of clinical practice. Supplement.

[287] G. Tognoni,et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin , 2007, Journal of thrombosis and haemostasis : JTH.

[288] V. Gudnason,et al. Increasing glucose levels and BMI predict future heart failure Experience from the Reykjavík Study , 2007, European journal of heart failure.

[289] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[290] F. McAlister,et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review , 2007, BMJ : British Medical Journal.

[291] N. Mutrie,et al. Physical activity consultation for people with Type 2 diabetes. Evidence and guidelines , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[292] P. Grant. Diabetes mellitus as a prothrombotic condition , 2007, Journal of internal medicine.

[293] S. Bangalore,et al. Fixed-dose combinations improve medication compliance: a meta-analysis. , 2007, The American journal of medicine.

[294] C. Granger,et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. , 2007, Archives of internal medicine.

[295] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.

[296] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[297] S. van Dulmen,et al. Patient adherence to medical treatment: a review of reviews , 2007, BMC Health Services Research.

[298] A. Avogaro,et al. Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients: The DAI Study , 2007, Stroke.

[299] Will G. Hopkins,et al. Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors for Complications in Type 2 Diabetic Patients: a Meta-Analysis , 2007, Diabetes Care.

[300] G. Bray,et al. Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes , 2007, Diabetes Care.

[301] R. Peto,et al. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double‐blind trial , 2007, Journal of internal medicine.

[302] Nicola J Cooper,et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[303] Parvez Hossain,et al. Obesity and diabetes in the developing world--a growing challenge. , 2007, The New England journal of medicine.

[304] Nutrition Recommendations and Interventions for Diabetes , 2007, Diabetes Care.

[305] J. Woodcock,et al. Putting evidence into practice: Smoking Cessation. Summer 2007, , 2007 .

[306] G. Moneta,et al. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes , 2007 .

[307] F. Boccara. Coronary intervention for persistent occlusion after myocardial infarction. , 2007 .

[308] M. Hersberger,et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[309] R. Shannon,et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. , 2006, Journal of cardiac failure.

[310] David M Nathan,et al. The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study , 2006, Diabetes.

[311] L. Rydén,et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. , 2006, European heart journal.

[312] J. Ferrières,et al. Prognosis of patients with atherothrombotic disease: a prospective survey in a non-hospital setting. , 2006, International journal of cardiology.

[313] M. Laakso,et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[314] S. Hernández-Díaz,et al. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications , 2006, BMC Medicine.

[315] L. Wallentin,et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study , 2006, The Lancet.

[316] Stuart Russell,et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[317] L. Rydén,et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart , 2006, Heart.

[318] Christopher P Cannon,et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[319] Eric Boerwinkle,et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. , 2006, Archives of internal medicine.

[320] Peter Jüni,et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. , 2006, American heart journal.

[321] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[322] G. Mancia,et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.

[323] J. Tuomilehto,et al. Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes , 2006, Diabetologia.

[324] M. Quon,et al. Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms , 2006, Circulation.

[325] A. Kastrati,et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[326] M. Mclean,et al. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. , 2006, Diabetes care.

[327] I. Poornima,et al. Diabetic cardiomyopathy: the search for a unifying hypothesis. , 2006, Circulation research.

[328] L. Shaw,et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. , 2006, European heart journal.

[329] Po Box,et al. Excess risk of fatal coronary heart disease associated with diabetes in men and women:meta-analysis of 37 prospective cohort studies , 2006 .

[330] Colin Baigent,et al. Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.

[331] G. Mensah,et al. Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II). , 2005, American journal of preventive medicine.

[332] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[333] M. Stumvoll,et al. Contraindications can damage your health—is metformin a case in point? , 2005, Diabetologia.

[334] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[335] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[336] F. Fernández‐Avilés,et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.

[337] R. Collins,et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.

[338] T. Rea,et al. Diabetes, glucose level, and risk of sudden cardiac death. , 2005, European heart journal.

[339] Ross T Tsuyuki,et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. , 2005, Diabetes care.

[340] P. Whelton,et al. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2005 .

[341] B. Frier,et al. Hypoglycaemia and cognitive function , 2005, Diabetes, obesity & metabolism.

[342] R. Giugliano,et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. , 2005, Journal of the American College of Cardiology.

[343] P. Rothwell,et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack , 2005, The Lancet.

[344] J Herlitz,et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. , 2005, European heart journal.

[345] M. Simoons,et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. , 2005, European heart journal.

[346] Darren K Mcguire,et al. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. , 2005, European heart journal.

[347] Neil Chapman,et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.

[348] J. Tuomilehto,et al. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. , 2005, Journal of the American College of Cardiology.

[349] J. Kostis,et al. The association of heart failure with insulin resistance and the development of type 2 diabetes. , 2005, American journal of hypertension.

[350] C. Byrne,et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[351] P. Moulin,et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. , 2005, Diabetes care.

[352] J. Cade,et al. Group based training for self-management strategies in people with type 2 diabetes mellitus. , 2005, The Cochrane database of systematic reviews.

[353] Bo Christensen,et al. Motivational interviewing: a systematic review and meta-analysis. , 2005, The British journal of general practice : the journal of the Royal College of General Practitioners.

[354] L. Chambless,et al. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. , 2005, Diabetes care.

[355] Vilmundur Gudnason,et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. , 2005, Diabetes care.

[356] H. Krumholz,et al. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[357] P. Dyck,et al. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[358] K. Chad,et al. Home versus center based physical activity programs in older adults. , 2005, The Cochrane database of systematic reviews.

[359] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[360] P. Deedwania,et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. , 2005, American heart journal.

[361] B. Brenner,et al. Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.

[362] J. Jimeno Mollet,et al. [Variability in the calculation of coronary risk in type-2 diabetes mellitus]. , 2005, Atencion primaria.

[363] J. Basora,et al. [The Framingham function overestimates stroke risk for diabetes and metabolic syndrome among Spanish population]. , 2005, Atencion primaria.

[364] Claude Bouchard,et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.

[365] G Hu,et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study , 2004, Diabetologia.

[366] Gareth Ambler,et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[367] M. Uusitupa,et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus , 2005 .

[368] M. Engelgau,et al. Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. , 2004, Diabetes technology & therapeutics.

[369] Seppo Lehto,et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. , 2004, Diabetes care.

[370] L. Rydén,et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. , 2004, European heart journal.

[371] Roberto Ferrari,et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[372] S. Solomon,et al. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials , 2004, Circulation.

[373] N. Day,et al. Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.

[374] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[375] J. McMurray,et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. , 2004, Journal of the American College of Cardiology.

[376] M. Bourassa,et al. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). , 2004, Journal of the American College of Cardiology.

[377] G. Davı̀,et al. Platelet activation in type 2 diabetes mellitus , 2004, Journal of thrombosis and haemostasis : JTH.

[378] I. Shapira,et al. Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients. , 2004, The Annals of thoracic surgery.